D'Arminio Monforte Antonella, Tavelli Alessandro, Bai Francesca, Tomasoni Daniele, Falcinella Camilla, Castoldi Roberto, Barbanotti Diletta, Mulè Giovanni, Allegrini Marina, Suardi Elisa, Tesoro Daniele, Tagliaferri Gianmarco, Mondatore Debora, Augello Matteo, Cona Andrea, Beringheli Tomaso, Gemignani Nicole, Sala Matteo, Varisco Benedetta, Molà Francesco, Pettenuzzo Sofia, Biasioli Lorenzo, Copes Alessandro, Gazzola Lidia, Viganò Ottavia, Tincati Camilla, De Bona Anna, Bini Teresa, Marchetti Giulia
Institute of Infectious Diseases, Department of Health Science, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
Life (Basel). 2021 Sep 17;11(9):979. doi: 10.3390/life11090979.
Mortality rate from COVID-19 in Italy is among the world's highest. We aimed to ascertain whether there was any reduction of in-hospital mortality in patients hospitalised for COVID-19 in the second-wave period (October 2020-January 2021) compared to the first one (February-May 2020); further, we verified whether there were clusters of hospitalised patients who particularly benefitted from reduced mortality rate.
Data collected related to in-patients' demographics, clinical, laboratory, therapies and outcome. Primary end-point was time to in-hospital death. Factors associated were evaluated by uni- and multivariable analyses. A flow diagram was created to determine the rate of in-hospital death according to individual and disease characteristics.
A total of 1561 patients were included. The 14-day cumulative incidence of in-hospital death by competing risk regression was of 24.8% (95% CI: 21.3-28.5) and 15.9% (95% CI: 13.7-18.2) in the first and second wave. We observed that the highest relative reduction of death from first to second wave (more than 47%) occurred mainly in the clusters of patients younger than 70 years.
Progress in care and supporting therapies did affect population over 70 years to a lesser extent. Preventive and vaccination campaigns should focus on individuals whose risk of death from COVID-19 remains high.
意大利新冠肺炎死亡率位居全球前列。我们旨在确定在第二波疫情期间(2020年10月至2021年1月)因新冠肺炎住院的患者相比第一波疫情期间(2020年2月至5月),其院内死亡率是否有所降低;此外,我们还验证了是否存在从死亡率降低中特别受益的住院患者群体。
收集了与住院患者人口统计学、临床、实验室、治疗及预后相关的数据。主要终点是院内死亡时间。通过单变量和多变量分析评估相关因素。绘制流程图以根据个体和疾病特征确定院内死亡率。
共纳入1561例患者。第一波和第二波疫情期间,采用竞争风险回归得出的14天累积院内死亡发生率分别为24.8%(95%置信区间:21.3 - 28.5)和15.9%(95%置信区间:13.7 - 18.2)。我们观察到,从第一波到第二波死亡相对降幅最大(超过47%)的情况主要发生在70岁以下的患者群体中。
护理和支持治疗方面的进展对70岁以上人群的影响较小。预防和疫苗接种运动应聚焦于新冠肺炎死亡风险仍然较高的个体。